Sarepta Therapeutics (SRPT) Expected to Announce Quarterly Earnings on Wednesday

Sarepta Therapeutics (NASDAQ:SRPT) is expected to be announcing its Q4 2025 results after the market closes on Wednesday, February 25th. Analysts expect Sarepta Therapeutics to post earnings of ($0.87) per share and revenue of $390.9530 million for the quarter. Investors may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Wednesday, February 25, 2026 at 4:30 PM ET.

Sarepta Therapeutics Stock Down 4.0%

SRPT stock opened at $18.12 on Tuesday. Sarepta Therapeutics has a 52-week low of $10.41 and a 52-week high of $109.55. The company has a debt-to-equity ratio of 0.78, a current ratio of 2.95 and a quick ratio of 1.79. The firm has a market capitalization of $1.90 billion, a P/E ratio of -6.02, a P/E/G ratio of 0.47 and a beta of 0.39. The company’s 50 day simple moving average is $20.68 and its 200-day simple moving average is $20.24.

Analysts Set New Price Targets

Several brokerages have recently commented on SRPT. HC Wainwright restated a “sell” rating on shares of Sarepta Therapeutics in a research note on Tuesday, January 27th. Wells Fargo & Company lowered their target price on shares of Sarepta Therapeutics from $50.00 to $45.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 5th. Weiss Ratings restated a “sell (d)” rating on shares of Sarepta Therapeutics in a report on Monday, December 29th. Wall Street Zen cut Sarepta Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. Finally, Mizuho upgraded Sarepta Therapeutics from a “neutral” rating to an “outperform” rating and boosted their target price for the stock from $19.00 to $26.00 in a report on Wednesday, November 5th. Nine investment analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and six have given a Sell rating to the stock. According to MarketBeat, Sarepta Therapeutics currently has a consensus rating of “Hold” and an average target price of $33.84.

Insider Buying and Selling

In other Sarepta Therapeutics news, COO Ian Michael Estepan sold 13,187 shares of the business’s stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $22.31, for a total value of $294,201.97. Following the transaction, the chief operating officer directly owned 193,300 shares in the company, valued at $4,312,523. The trade was a 6.39% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 7.60% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Sarepta Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. AQR Capital Management LLC raised its position in Sarepta Therapeutics by 454.6% in the 4th quarter. AQR Capital Management LLC now owns 7,796,535 shares of the biotechnology company’s stock worth $167,781,000 after purchasing an additional 6,390,860 shares during the last quarter. First Trust Advisors LP raised its position in shares of Sarepta Therapeutics by 2.7% during the fourth quarter. First Trust Advisors LP now owns 1,992,577 shares of the biotechnology company’s stock worth $42,880,000 after acquiring an additional 52,796 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Sarepta Therapeutics by 10.6% during the fourth quarter. Geode Capital Management LLC now owns 1,904,325 shares of the biotechnology company’s stock worth $40,990,000 after acquiring an additional 183,201 shares during the last quarter. Federated Hermes Inc. lifted its stake in shares of Sarepta Therapeutics by 0.4% during the fourth quarter. Federated Hermes Inc. now owns 1,313,313 shares of the biotechnology company’s stock valued at $28,262,000 after acquiring an additional 4,622 shares during the period. Finally, Millennium Management LLC boosted its holdings in Sarepta Therapeutics by 251.9% in the fourth quarter. Millennium Management LLC now owns 1,000,109 shares of the biotechnology company’s stock valued at $21,522,000 after acquiring an additional 715,899 shares during the last quarter. Institutional investors and hedge funds own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.